Bryostatin 3

Bryostatin 3 is one of a series of cyclic macrolides isolated from the marine bryozoan Bugula neritina (Order Cheilostomata), and a potent modulator of Protein Kinase C (PKC).

Bryostatin 3, unlike Bryostatin 1, has not been extensively studied for its bioactivity. It was originally isolated from B. neritina based on its antineoplastic activity. It shows phorbol dibutyrate receptor displacement activity similar to that of Bryostatin 1. The bryostatins are known to bind and activate Protein Kinase C (PKC), though they differ from other phorbol ester tumor promoters in that they act as agonists or antagonists of PKC activity. Bryostatin 3 was found to act as an antagonist to phorbol ester tumor promoter TPA, preventing the inhibition of GH4 cell proliferation, similar to what has been observed in Bryostatin 1. Unlike Bryostatin 1, Bryostatin 3 also enhanced cell-substratum adhesion and did not block the increased adhesion observed from TPA.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
FAP014
Bryostatin 3, 50ug
50ug 1-2 weeks
Regular Price:$984.00
On Sale:
FAP013
Bryostatin 3, 10ug
10ug 1-2 weeks
Regular Price:$261.60
On Sale:
Specifications

Product Type: Small Molecule
Chemical Formula: C46H64O17
CAS number: 87370-86-3
Molecular Weight: 888.99
Format: White crystalline solid
Purity: >80 % determined by HPLC
Solubility: Soluble in methanol and ethanol
Stability: Stable as a solid over extended period at -20C.
Storage: -20C, avoid exposure to oxygen and direct sunlight
Shipped: Cold Pack

Data

Bryostatin 3 HPLC Chromatogram.


Purification Notes: Purified using near-critical and supercritical fluids as an alternate to conventional organic solvents during a sequence of phase extraction and chromatographic purification steps.

References
  1. Castor T. (1995,1997). Method and Apparatus for Extracting Taxol from Source Materials. US Patent No. 5,440,055 and European Patent No. 689,537.
  2. Castor T. (1998). Method and Apparatus for Isolating Therapeutic Compositions from Source Materials. US Patent No. 5,750,709.
  3. Castor T. (2001). Supercritical Fluid Isolation of Bryostatin 1. SBIR Phase II Final Report. SBIR Grant No. 5 R44 CA 64017-03.
  4. Davidson S, Allen S, Lim G, Anderson C and Haygood M. (2001). Evidence for the Biosynthesis of Bryostatins by the Bacterial Symbiont "Candidatus Endobugula sertula" of the Bryozoan Bugula neritina. Appl. Environ. Microbiol. 67, 4531-4537.
  5. Mackanos E, Pettit G and Ramsdell J. (1991). Bryostatins selectively regulate protein kinase C- mediated effects on GH4 cell proliferation. J Biol Chem. 266: 11205-11212.
  6. Pettit G, Herald C, and Kamano Y. (1983). Antineoplastic agents. 93. Structure of the Bugula neritina (marine bryozoan) antineoplastic component Bryostatin 3. J Org Chem 48: 5354-5356.
  7. Schaufelberger D, Chmurny G, Beutler J, Koleck M, Alvarado B, Schaufelberger B, and Muschik G. (1991a). Revised structure of Bryostatin 3 and isolation of the Bryostatin 3 26-ketone from Bugula neritina. J Org Chem 56: 2895-2900.
  8. Schaufelberger D, Koleck M, Beutler J, Vatakis A, Alvarado A, Andrews P, Marzo L, Muschik G, Roach J, Ross J, Lebherz W, Reeves M, Eberwein R, Rodgers L, Testerman R, Snader K and Forenza S. (1991). The large scale isolation of Bryostatin 1 from Bugula neritina following good manufacturing practices. Journal of Natural Products. 54, 1265-1270.

If you publish research with this product, please let us know so we can cite your paper.

Loading...